Using a 3D Culture Model for Circulating Tumor Cells Combined With Molecular Bioassays in Patients With HNSCC Cancer

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorChang Gung Memorial Hospital

About this trial

Cancer has been a significant cause of human death in the recent two decades, although detection, diagnosis, and cancer treatments improved and evolved rapidly. Till now, the reasons why some cancer recurs and others do not remain unclear. Since 2004, circulating tumor cell (CTC) has been well-recognized that CTCs in the circulatory system are associated with cancer metastasis. The fundamental studies of CTCs hold tremendous potentials for probing the biological insights on the molecular mechanisms underlying cancer metastasis, cancer-related gene mutation, or biomarker discovery. However, the low purity (one of the natural limitations) of isolated samples often hampered CTC-directed studies' utility. For that, investigators used a well-established device (ODEP, optically-induced-dielectrophoresis) to isolate viable and high-purity CTCs for the following investigations. Investigators team developed a protocol in the past months and succeeded in cultivating CTCs (near 100%) for further drug tests and had a technology platform of organoid culture system developing in 2020. The preliminary results of the experiments showed a promising combination. That urges investigators to propose a 3-year project investigating CTC culture in the organoid system to look at (1) the behavior of CTCs in organ cell background (organoid), (2) the influences of different background cells, (3) the different in-vitro (or in-organoid) response of CTCs to specific drugs (pembrolizumab, nivolumab, cetuximab, cisplatin, 5-FU, taxanes) of head and neck squamous cell carcinoma. In the meantime, investigators will look at the genomic alterations of those CTCs growing fast and well in the organoid systems to find possible precipitating metastasis genes at a scale of cell (CTC) level. Investigators believe that the project is doable and possibly help human cancer control and understanding.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

age ≥ 18

agree with blood drawing and follow the procedure of the trial

Disqualifiers

health participants:with serious illness

cancer participants:none

Trial population

Develop the CTC culture system (isolated by negative selection strategy and ODEP platform) and organoid 3D culture system for CTC from health participants and HNSCC cancer participants.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Organoid 3D culture

    Other intervention

    Investigate different normal cells (lung, bone, soft tissue, liver, etc) as metastatic organs to simulate the behaviors of CTCs in metastatic sites

Treatment groups

88 Participants
are divided into 2 treatment groups
Group A: control1 intervention
Group B: experimental1 intervention

Trial outcomes

Primary outcomes

1

cell density and numbers

CTC number low(\<10) and high(\>100)

Time frame
baseline
2

cytokines detection-EpCAM

For negative selection of CTCs by the negative selection system.To deplete EpCAM leukocytes, a EpCAM depletion cocktail was mixed with the collected nucleated cells

Time frame
baseline
3

cytokines detection-CD-45+ leukocytes

For negative selection of CTCs by the negative selection system.To deplete CD-45+ leukocytes, a CD-45 depletion cocktail was mixed with the collected nucleated cells

Time frame
baseline
4

counting of EpiCAM-positive and Hoechst-positive cells

Positive Selection method.The cell recovery is determined by counting EpiCAM-positive and Hoechst-positive cells under microscope with hemocytometer. Human samples will go through the whole processes without spiking steps

Time frame
baseline

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.